PT - JOURNAL ARTICLE AU - Espinola, Natalia AU - Loudet, Cecilia I. AU - Luxardo, Rosario AU - Moreno, Carolina AU - Kyaw, Moe H. AU - Spinardi, Julia AU - Mendoza, Carlos Fernando AU - Carballo, Carolina M. AU - Dantas, Ana Carolina AU - Abalos, Maria Gabriela AU - Ballivian, Jamile AU - Navarro, Emiliano AU - Bardach, Ariel TI - COVID-19 disease and economic burden in adults in six Latin American Countries before nationwide vaccination program: Ministry of Health databases assessment and systematic literature review AID - 10.1101/2024.10.31.24316541 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.31.24316541 4099 - http://medrxiv.org/content/early/2024/11/02/2024.10.31.24316541.short 4100 - http://medrxiv.org/content/early/2024/11/02/2024.10.31.24316541.full AB - Introduction and objective The COVID-19 pandemic had a significant disease burden on the healthcare system worldwide. There is limited reliable national data on COVID-19 associated morbidity, mortality, and healthcare costs in Latin America. This study explored the COVID-19 disease and economic burden in Argentina, Brazil, Chile, Colombia, Mexico, and Peru in the pre-vaccination period.Methods We analyzed national databases and conducted a systematic review of the published literature on COVID-19 in adults aged 18 years and above. We reported cases, death rates, years of life lost, and excess mortality associated with COVID-19 in pre-vaccination period. In addition, we used a cost of illness analysis to estimate the direct medical costs associated with COVID-19. All costs are reported in US dollars as of 2023.Results Before the national COVID vaccination program rollout, the average incidence rate of COVID-19 in adults aged 18 and above was 6,741 per 100,000 persons. Approximately 91% of the cases were mild, 7% were moderate/severe, and 2% were critical. Among 2,201,816 hospitalized cases, 27.8% were in intensive care, and 17.5% required mechanical ventilation. The country-specific data varied greatly across Latin American countries, with hospitalization admission: 469-18,096 per 100,000, excess mortality: 76-557 per 100,000, and years of life lost: 241,089-3,312,346. Direct medical costs ranged from US$258 million to US$10,437 million, representing approximately 2%-5% of national health expenditure.Conclusion COVID-19 imposed a substantial public health and economic burden on Latin American countries during the pre-vaccination period. The findings should help policymakers to make informed decisions and allocate resources effectively to improve national strategies around surveillance, preventive and treatment strategies to control the spread of COVID-19 disease in the future.Competing Interest StatementI have read the journal's policy and Julia Spinardi Moe H. Kyaw Carlos Fernando Mendoza Carolina M. Carballo, and Celina G. Vega have the following competing interests: they are employees of Pfizer. The rest of the authors have declared that no competing interests exist.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll data involved in this study are included in the main manuscript and its supplementary information files.